• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Protonix (pantoprazole sodium)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – October 2011

 

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience:
  • weight changes, hyponatremia, asthenia, fatigue and malaise, insomnia and somnolence

 

DRUG INTERACTIONS

Clopidogrel
  • co-administration of clopidogrel with pantoprazole reduces the pharmacological activity of clopidogrel

 

also see:

 

  • Pharmacokinetics: information about the drug-drug interaction between pantoprazole and clopidogrel.